In addition to mediating bone loss, IL-6 is considered a negative prognostic marker in many types of cancer and has been found to promote malignant cell proliferation, metastasis and anti-apoptotic pathways, therefore favoring disease progression (Kumari et al., 2016). Here, IL6 is linked to cancer.